ibux 50 mg/ g
karo pharma as - ibuprofen - gel - 50 mg/ g
ibux 50 mg/ g
karo pharma as - ibuprofen - gel med mentol - 50 mg/ g
ibux 200 mg
karo pharma as - ibuprofen - kapsel, myk - 200 mg
ibux 400 mg
karo pharma as - ibuprofen - kapsel, myk - 400 mg
ibux 200 mg
karo pharma as - ibuprofen - tablett, filmdrasjert - 200 mg
ibux 400 mg
karo pharma as - ibuprofen - tablett, filmdrasjert - 400 mg
comboval 10 mg/ ml / 3 mg/ ml
laboratoire aguettant - paracetamol / ibuprofennatriumdihydrat - infusjonsvæske, oppløsning - 10 mg/ ml / 3 mg/ ml
dolerin 500 mg / 150 mg
vale pharmaceuticals limited - paracetamol / ibuprofen - tablett, filmdrasjert - 500 mg / 150 mg
eucreas
novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.
icandra (previously vildagliptin / metformin hydrochloride novartis)
novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, type 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgjengelige data på forskjellige kombinasjoner).